V Wealth Managementllc buys $1212847 stake in Amgen (AMGN)
Nov 02 2016 by Marjorie Miles
For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $2.95 per share according to consensus of 9 analysts. During the same quarter in the prior year, the company posted $2.72 earnings per share.
Analysts also projected the Maximum, Minimum and Mean Earnings per share Estimate for Next Quarter.
Other equities analysts also recently issued reports about the company. Amgen makes up approx 0.67% of Mercer Capital Advisers's portfolio.Meeder Asset Management Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 9,024 additional shares and now holds a total of 33,893 shares of Amgen which is valued at $5,517,780. The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 2.35 on scale of 1-5. Amgen has a one year low of $139.02 and a one year high of $176.85.
Want to receive stock recommendations on Amgen Inc. Vetr upgraded Amgen from a "sell" rating to a "hold" rating and set a $171.34 price objective for the company in a report on Wednesday, August 3rd.
Some buy side analysts are also providing their Analysis on Amgen Inc., where 2 analysts have rated the stock as Strong buy, 10 analysts have given a Buy signal, 11 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. Amgen now has an average rating of "Buy" and an average price target of $183.59. Amgen (AMGN) recently declared that it will present detailed results from the Phase 3 coronary intravascular imaging trial, the GLAGOV (GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound) study, at the forthcoming American Heart Association (AHA) Scientific Sessions 2016, being held November 12-16 in New Orleans. The stock has a 50 day moving average of $165.60 and a 200-day moving average of $162.52.
The company's price to free cash flow for trailing twelve months is 18.21. Amgen, Inc. (NASDAQ:AMGN) has a market capitalization of $98.23B and most recently 745M outstanding shares have been calculated.
Hellish opening weekend for Tom Hanks' 'Inferno'
From just 302 screens, it collected $2.1 million, which equates to a solid $7,070 per-screen average and a #10 finish. With a 50% decline in attendance, 'Ouija: Origin of Evil' managed to earn another $7 million.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, October 27th. The firm had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.73 billion. Amgen had a return on equity of 29.73% and a net margin of 33.63%. The business's quarterly revenue was up 1.5% compared to the same quarter a year ago.
EPS growth in next year is estimated to reach 10.04% while EPS growth estimate for this year is set at 35.20%.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock.
By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Amgen Inc.
During last 5 trades the stock sticks nearly -11.09%. The company stock was initiated at Hold, wrote analysts at Gabelli & Co, in a research note issued to clients on Friday August 26, 2016. Parsec Financial Management Inc. increased its position in shares of Amgen by 2.2% in the second quarter. Badgley Phelps & Bell Inc. now owns 49,799 shares of the medical research company's stock worth $7,577,000 after buying an additional 21,649 shares during the last quarter. Nelson Roberts Investment Advisors LLC acquired a new stake in shares of Amgen during the third quarter worth approximately $123,000. Meag Munich Ergo Kapitalanlagegesellschaft MBH increased its stake in shares of Amgen by 99.1% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company's stock valued at $141,000 after buying an additional 3 shares during the last quarter. Such Annette Louise offloaded 3,000 shares in the company at a per-share price of $174.59 and ended up generating $523,770 in proceeds. The Stock Closing Price on the 7th day of earnings was $152.37. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The company's management has announced Nov 14, 2016 as the ex-dividend date and fixed the record date on Nov 16, 2016. The dividend payable date has been fixed on Dec 8, 2016.